HMOX1 and melanoma: Preclinical studies in mouse models showed that targeting HO‐1 by the inhibitor SnPPIX resulted in a therapeutic effect15 and synergized with chemotherapy,14 while HO‐1 inhibition with another inhibitor, OB 24, overcame resistance to immunotherapy in a mouse melanoma model and was used to improve checkpoint inhibitors therapy.16